A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) (F-GENE)

A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) in Families With Kinship Bonds and at Least One Homozygous Patient

This is a prospective, non-drug epidemological cohort study aimed to investigate the relatives of these cases with CTX-specific gene mutation and clinical features of CTX disease over CTX index cases diagnosed with CTX disease throughout the clinics in Turkey. Relatives included in the study (relatives of CTX index cases) will be taken into clinical and genetic evaluation. Relatives will not receive any experimental intervention or treatment because of their participation in the study. Therefore, this study does not include a treatment protocol or does not have a predetermined visit flow chart. However, relatives of CTX index cases should give consent to genetic testing.

Study Overview

• Status: Enrolling by invitation
• Conditions: Xanthomatosis, Cerebrotendinous
• Intervention / Treatment: Genetic: Mutation Analysis

Detailed Description

WORK DESIGN STAGES:

1. The CTX index case will be identified and the CTX genetics will be reapproved. The following steps will be provided for all cases.

   • Re-validation of CTX genetics: Cases of CTX indexes that are unrelated and clearly identified the CTX homozygous inheritance identified in the CYP27A1 gene by kinship.
   • Documenting the nuclear and extended family structure and extracting family trees (interview with index cases and parents of index cases)
   • Documentation of all potential symptoms compatible with CTX disease, including data based on the CTX suspicion index (Mignarri Index) in the nuclear and extended family
   • Documentation of patients who have died due to unexpected death or unwillingness to participate in the study.
   • Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
   • Collecting blood samples from index cases and, where possible, all nuclear family members (such as parents and siblings)

2. The target cohort will be defined in each family according to the interview results. If the study physician predicts that there are fewer than 50 patients in a large family for the study and follow-up period, this family will be excluded from the study. The initial objective will be to involve grandparents, all their children, married wives and grandchildren. This choice can be adapted by the physician depending on the special situation in the family according to the results of individuals who have undergone genetic mutation tests in the nuclear family, if any, and the definition of nuclear and extended relatives may change in consanguineous families. All extended family members of each identified CTX case will be invited to perform the following steps:

   • Genetic counseling (ideally per family)
   • Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara) and no samples will be stored after the analysis and all samples will be destroyed. Documentation of key data for each case
   • Confirming that the family tree is correctly identified.
   • Documenting patients who have died due to unexpected death or unwillingness to participate in the study.
   • Perform limited neurological examination for key signs and symptoms and document it according to the CTX suspicion index (Mignarri Index).
3. Testing all samples by DNA sequencing for the identified mutation analysis. According to the results, large family cohort will be extracted. In some families, this number can reach up to 600-800 cases.
4. Re-inviting all study cases with disease genotypes for extended neurological examination and medical / genetic counseling.
5. To offer genetic counseling to all study patients with carrier genotypes so that they can make informed decisions about marriage and the next generation (the study coordinator will propose the medical follow-up of new cases diagnosed genetically as CTX).

• Study Type: Observational
• Enrollment (Anticipated): 800

Contacts and Locations

Study Locations

• Turkey
  • Osmaniye, Turkey
    • Osmaniye / Index Case 1 Family Village

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The family of each CTX index case should have more than 50 members in at least three generations. All the family members of the CTX index cases will be asked for sampling.

Description

Inclusion Criteria:

• The family of each CTX index case should have more than 50 members in at least three generations.
• CTX index cases should be from different families.
• Index cases and relatives and / or legal representatives are required to be willing to give written informed consent.

Exclusion Criteria:

• Relatives of unconfirmed CTX index cases or non-homozygous CTX patients for disease-causing CTX mutation.
• The patient and / or his / her legal representative does not consent to participate in the study.

Study Plan

How is the study designed?

Design Details

• Observational Models: Family-Based
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of CTX mutation	Frequency of CTX mutation (affected or carrier mutation) among relatives	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Signs or symptoms compatible with CTX disease	Proportion of cases and relatives with current and / or past signs or symptoms compatible with CTX disease	1 year
Mignarri Index	CTX disease scoring index values	1 Year
Pedigree	A family tree of the index case	1 year

Collaborators and Investigators

• Sponsor: TRPHARM
• Collaborators: Klinar CRO; Damagen Genetic Diagnostic Center
• Investigators: Principal Investigator: Hasan Onal, Asc. Prof., Kanuni Sultan Suleyman University Hospital, Pedaitric Metabolism

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2019
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): March 1, 2022

Study Registration Dates

• First Submitted: January 2, 2020
• First Submitted That Met QC Criteria: January 3, 2020
• First Posted (Actual): January 6, 2020

Study Record Updates

• Last Update Posted (Actual): April 1, 2021
• Last Update Submitted That Met QC Criteria: March 30, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: CTX, Relatives, Index Cases, Kinship, Pedigree
• Additional Relevant MeSH Terms: Metabolic Diseases; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Lipid Metabolism Disorders; Lipid Metabolism, Inborn Errors; Xanthomatosis, Cerebrotendinous; Xanthomatosis
• Other Study ID Numbers: TR-CTX-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No